<DOC>
	<DOCNO>NCT02173301</DOCNO>
	<brief_summary>The purpose study : 1 . To evaluate efficacy 3 dos XP23829 compare placebo treatment moderate-to-severe chronic plaque-type psoriasis . 2 . To evaluate safety tolerability XP23829 subject psoriasis . 3 . To evaluate pharmacodynamics ( PD ) XP23829 immunological analysis peripheral blood sample .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety XP23829 Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Male female subject , age ≥ 18 . 2 . Stable , moderatetosevere plaquetype psoriasis diagnose least 6 month prior randomization ( morphology change significant flare disease activity last 6 month opinion investigator ) . 3 . Severity disease meeting follow three criterion prior randomization : 1 . Psoriasis Area Severity Index ( PASI ) score 12 great 2 . Total Body Surface Area ( BSA ) affect plaque psoriasis 10 % great 3 . Static Physician 's Global Assessment ( sPGA ) score 3 great 4 . Must candidate phototherapy and/or systemic therapy psoriasis . 1 . Subjects current inverse , erythrodermic , predominantly guttate , pustular psoriasis . 2 . Subjects current druginduced drugexacerbated psoriasis . 3 . Subjects moderatetosevere psoriatic arthritis type ; subject mild psoriatic arthritis , require systemic diseasemodifying therapy . 4 . Subjects unstable significant illness , include presence laboratory abnormality screen opinion investigator would place subject unacceptable risk he/she participate study . 5 . Any skin condition ( e.g . eczema ) confound ability interpret data study . 6 . Treatment topical antipsoriatic therapy within 14 day prior randomization ( include topical steroid , topical vitamin A D analog preparation , tacrolimus , pimecrolimus , anthralin ) . 7 . Phototherapy prolong sun exposure use ultraviolet ( UV ) light source within 28 day randomization . 8 . Use investigational approve biologic treatment know affect psoriasis , adalimumab , etanercept , golimumab infliximab within 12 week randomization ustekinumab within 24 week randomization . 9 . Use systemic medication ( nonbiologics ) know affect psoriasis ( include limit oral corticosteroid , cyclosporine , methotrexate , lithium , betaadrenergic blocker ) within 4 week randomization , 5 halflives , whichever longer . 10 . Prior treatment Dimethyl Fumarate ( Fumaderm® Tecfidera® ) Fumaric Acid Ester ( FAE ) containing product . 11 . Have fail ( due inadequate response ) 3 approved systemic agent treatment psoriasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>